NetworkNewsBreaks Archive - Page 494 of 2081

ThursdayAug 03, 2023 12:48 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, released an update on its ongoing clinical study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. According to the report, the company continues to see rapid progression and acceleration of enrollment for the study, with 180 patients of the 243 expected currently enrolled across 46 clinical trial sites. In addition, CNS has documented the necessary number of patients reaching the primary efficacy endpoint, or overall survival, to conduct…

ThursdayAug 03, 2023 12:06 pm

NetworkNewsBreaks – CISO Global Inc. (NASDAQ: CISO) Bolsters Argo Platform to Aggregate Real-Time Data, Improve Security Decision Making

CISO Global Inc. (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, has strengthened its security management platform Argo to increase the effectiveness of security teams who now can access real-time data across tool sets to make better informed decisions. The platform has the capability to aggregate data in real time from a client's entire environment, including network asset information, currently deployed cyber tools, security operations center (“SOC”) services, vulnerability management, secure managed IT and penetration testing data. Using this information, enterprises can build individual risk profiles for each network asset to better prioritize cybersecurity threats based…

ThursdayAug 03, 2023 11:23 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) UNBUZZD Definitive Agreement Featured by Investment Pitch Media

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, is spotlighted on the latest InvestmentPitch Media release. The media release discusses FSD Pharma’s recently executed definitive agreement that grants exclusive rights to Celly Nutrition for recreational applications of its alcohol misuse technology and the launch of UNBUZZD(TM), a revolutionary rapid alcohol detoxification drink. According to the agreement, Celly Nu will pay FSD a license fee by issuing 100,000,000 shares and a 7% royalty on gross revenue if…

ThursdayAug 03, 2023 11:14 am

NetworkNewsBreaks – GEMXX Corporation (GEMZ) Mobilizes Mining Equipment to Canada-Based Snow Creek Mine

GEMXX (OTC: GEMZ), a leader in the Ammolite gemstone mine-to-market space, has mobilized equipment to its Snow Creek Mine site for the mining season. The move, which brings the property to full production, was made in association with Crazy Horse Mining Inc. (“CHMI”), which GEMXX has partial ownership in. According to the announcement, site preparation has been taking place in the Snow Creek mine area, including preparing access roads and pads for equipment and ponds. Now that equipment has been moved to the site, the company anticipates processing 1,000 cubic yards of gold bearing ore per day. GEMXX and CHMI…

WednesdayAug 02, 2023 4:06 pm

NetworkNewsBreaks – Benchmark Company Raises Price Target on D-Wave Quantum Inc. (NYSE: QBTS)

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software and services and the world’s first commercial supplier of quantum computers, was featured in a recent equity research report published by The Benchmark Company LLC. The publication covers three public quantum computing companies, including D-Wave, and discusses a shifting in investor sentiment with quantum computing stocks in the report significantly outperforming the tech sector as the AI theme gathers momentum. An excerpt of the report reads, “QBTS - Our $3 price target (up from $2) is based on a 5.2x EV/Sales multiple on our current 2026E revenue projections. We…

WednesdayAug 02, 2023 1:34 pm

NetworkNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Announces Pricing for $2.75M Public Offering

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-government, Internet of Things (“IoT”) and cybersecurity sectors, announced the pricing of its current public offering of 3,235,295 units at a public offering price of $0.85 per unit. According to the announcement, each unit includes one ordinary share (or a prefunded warrant in lieu thereof) and one warrant to purchase one ordinary share. The company noted that the common warrants will be immediately exercisable at an exercise price of $0.85 per share with an expiration date five years from the date of issue. The announcement noted that gross proceeds from the public offering, which…

WednesdayAug 02, 2023 1:32 pm

NetworkNewsBreaks – Why First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) Is ‘One to Watch’

First Tellurium (CSE: FTEL) (OTC: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper, and tungsten, for North American markets. “This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA. First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential,” a recent article reads. “Deer Horn is one of…

WednesdayAug 02, 2023 1:24 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Designing Human Clinical Study of DehydraTECH-CBD for Weight Loss, Diabetes Control

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today reported its intention to conduct a human clinical study to examine DehydraTECH-CBD for purposes of diabetes control and weight loss. Lexaria previously announced that, in its pre-clinical diabetes study DIAB-A22-1 in obese diabetic-conditioned animals, DehydraTECH-CBD achieved each of the following: lowered blood glucose levels by 19.9%; lowered overall body weight by 7% sustained over eight weeks; statistically significant increase in locomotor activity; lowered triglyceride levels by more than 25%; and lowered blood urea nitrogen levels by 27.9%. As a result of the very successful pre-clinical results, Lexaria…

WednesdayAug 02, 2023 1:03 pm

NetworkNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Expands Phase 2 Trial to Add New Site

IGC Pharma (NYSE American: IGC) today announced the addition of an important trial site at the University of Puerto Rico network as an expansion of its ongoing phase 2 clinical trial investigating lead drug asset, IGC-AD1, as a treatment for lowering agitation in patients with Alzheimer’s disease. According to clinicaltrials.gov, IGC-AD1 is the only natural THC-based investigational drug undergoing FDA trials. The therapy relies on low doses of THC and another compound as pharmaceutical active agents for the treatment of Alzheimer’s and, in pre-clinical and phase 1 studies, has shown the potential to be effective in ameliorating Aβ plaques and…

WednesdayAug 02, 2023 12:55 pm

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Launch UNBUZZD

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders. The company today announced its entry into a definitive agreement with Celly Nutrition Inc. to grant exclusive rights to recreational applications for FSD Pharma’s alcohol misuse technology and launch UNBUZZD. A revolutionary, rapid alcohol detoxification drink, UNBUZZD was created by scientists and the expert clinical research team at FSD Pharma. “This is a major milestone for our company,” said Zeeshan Saeed, founder, CEO and executive co-chairman of the…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks